{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:47:43Z","timestamp":1782388063919,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Horizon Europe PharmaGenHUB Project","award":["101059870"],"award-info":[{"award-number":["101059870"]}]},{"name":"Ministry of Science, Technological Development and Innovation","award":["451-03-136\/2025-03\/200042"],"award-info":[{"award-number":["451-03-136\/2025-03\/200042"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00440-z","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:06:09Z","timestamp":1779375969000},"page":"791-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0759-0553","authenticated-orcid":false,"given":"Isidora","family":"Curic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-9258","authenticated-orcid":false,"given":"Nikola","family":"Kotur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-7345","authenticated-orcid":false,"given":"Bojan","family":"Ristivojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-867X","authenticated-orcid":false,"given":"Djordje","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-7867","authenticated-orcid":false,"given":"Marina","family":"Jelovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6544-4876","authenticated-orcid":false,"given":"Katarina","family":"Krstajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8838-1521","authenticated-orcid":false,"given":"Mia","family":"Radosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-6698","authenticated-orcid":false,"given":"Ana","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8363-680X","authenticated-orcid":false,"given":"Sonja","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-6069","authenticated-orcid":false,"given":"Jelena","family":"Roganovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-6330","authenticated-orcid":false,"given":"Branka","family":"Zukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"9","key":"440_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrc1164","volume":"3","author":"MF Greaves","year":"2003","unstructured":"Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"440_CR2","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3390\/cancers12123671","volume":"12","author":"F Coluzzi","year":"2020","unstructured":"Coluzzi F, Rocco M, Green Gladden R, Persiani P, Thur LA, Milano F. Pain management in childhood leukemia: diagnosis and available analgesic treatments. Cancers. 2020;12(12):3671.","journal-title":"Cancers"},{"issue":"11","key":"440_CR3","first-page":"3310","volume":"95","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et\u00a0al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310\u201322.","journal-title":"Blood"},{"issue":"4","key":"440_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.leu.2401723","volume":"14","author":"H McLeod","year":"2000","unstructured":"McLeod H, Krynetski E, Relling M, Evans W. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14(4):567\u201372.","journal-title":"Leukemia"},{"issue":"2","key":"440_CR5","first-page":"256","volume":"2","author":"R Franca","year":"2019","unstructured":"Franca R, et\u00a0al. Pharmacogenetics of thiopurines. CDR. 2019;2(2):256.","journal-title":"CDR"},{"issue":"23","key":"440_CR6","doi-asserted-by":"publisher","first-page":"37761","DOI":"10.18632\/oncotarget.17781","volume":"8","author":"SG Liu","year":"2017","unstructured":"Liu SG, Gao C, Zhang RD, Zhao XX, Cui L, Li WJ, et\u00a0al. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017;8(23):37761\u201372.","journal-title":"Oncotarget"},{"issue":"10","key":"440_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011;67(10):993\u20131006.","journal-title":"Eur J Clin Pharmacol"},{"issue":"27","key":"440_CR8","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et\u00a0al. Childhood acute lymphoblastic leukemia: progress through collaboration. JCO. 2015;33(27):2938\u201348.","journal-title":"JCO"},{"issue":"12","key":"440_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.757464","volume":"21","author":"Z Song","year":"2021","unstructured":"Song Z, Hu Y, Liu S, Jiang D, Yi Z, Benjamin MM, et\u00a0al. The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front Pharmacol. 2021;21(12):757464.","journal-title":"Front Pharmacol"},{"issue":"6","key":"440_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/tpj.2012.44","volume":"13","author":"E Lopez-Lopez","year":"2013","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2013;13(6):498\u2013506.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"440_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","volume":"33","author":"L Yang","year":"2012","unstructured":"Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol. 2012;33(5):1445\u201354.","journal-title":"Tumor Biol"},{"key":"440_CR12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282761","author":"S Du","year":"2023","unstructured":"Du S, Huang X, He X, Mao M, Chen M, Zhang R, et\u00a0al. Association of NUDT15 gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.282761.","journal-title":"Haematologica"},{"issue":"5","key":"440_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui C, Stein CM, et\u00a0al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update. Clin Pharma Ther. 2019;105(5):1095\u2013105.","journal-title":"Clin Pharma Ther"},{"issue":"4","key":"440_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1468-3083.2006.01459.x","volume":"20","author":"K Oender","year":"2006","unstructured":"Oender K, Lanschuetzer C, Laimer M, Klausegger A, Paulweber B, Kofler B, et\u00a0al. Introducing a fast and simple PCR-RFLP analysis for the detection of mutant thiopurine S-methyltransferase alleles TPMT*3A and TPMT*3C. Acad Dermatol Venereol. 2006;20(4):396\u2013400.","journal-title":"Acad Dermatol Venereol"},{"issue":"4","key":"440_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/genes11040468","volume":"11","author":"N Kotur","year":"2020","unstructured":"Kotur N, Lazic J, Ristivojevic B, Stankovic B, Gasic V, Dokmanovic L, et\u00a0al. Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes (Basel). 2020;11(4):468.","journal-title":"Genes (Basel)"},{"issue":"7571","key":"440_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"The 1000 Genomes Project Consortium, Auton A, Abecasis GR, Steering Committee, Altshuler DM, et\u00a0al. A global reference for human genetic variation. Nature. 2015;526(7571):68\u201374.","journal-title":"Nature"},{"issue":"3","key":"440_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cpt.463","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, et\u00a0al. Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharma Ther. 2017;101(3):373\u201381.","journal-title":"Clin Pharma Ther"},{"issue":"4","key":"440_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","volume":"139","author":"H Ochi","year":"2010","unstructured":"Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et\u00a0al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\u2014A genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139(4):1190-1197.e3.","journal-title":"Gastroenterology"},{"issue":"5","key":"440_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bcpt.13176","volume":"124","author":"A Citterio-Quentin","year":"2019","unstructured":"Citterio-Quentin A, El Mahmoudi A, Perret T, Conway A, Ryan A, Beringer A, et\u00a0al. Red blood cell IMPDH activity in adults and children with or without azathioprine: relationship between thiopurine metabolites, ITPA and TPMT activities. Basic Clin Pharma Tox. 2019;124(5):600\u20136.","journal-title":"Basic Clin Pharma Tox"},{"issue":"3","key":"440_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/genes10030191","volume":"10","author":"S Pavlovic","year":"2019","unstructured":"Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment. Genes. 2019;10(3):191.","journal-title":"Genes"},{"issue":"1","key":"440_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12929-016-0291-y","volume":"23","author":"NE Burgis","year":"2016","unstructured":"Burgis NE. A disease spectrum for ITPA variation: advances in biochemical and clinical research. J Biomed Sci. 2016;23(1):73.","journal-title":"J Biomed Sci"},{"issue":"1","key":"440_CR22","doi-asserted-by":"publisher","first-page":"e0191069","DOI":"10.1371\/journal.pone.0191069","volume":"13","author":"NC Peltenburg","year":"2018","unstructured":"Peltenburg NC, Bierau J, Bakker JA, Schippers JA, Lowe SH, Paulussen ADC, et\u00a0al. Erythrocyte Inosine triphosphatase activity: a potential biomarker for adverse events during combination antiretroviral therapy for HIV. PLoS ONE. 2018;13(1):e0191069 (Men\u00e9ndez-Arias L, editor).","journal-title":"PLoS ONE"},{"issue":"5","key":"440_CR23","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1074\/jbc.M609838200","volume":"282","author":"P\u00e5 Stenmark","year":"2007","unstructured":"Stenmark P\u00e5, Kursula P, Flodin S, Gr\u00e4slund S, Landry R, Nordlund P, et\u00a0al. Crystal structure of human inosine triphosphatase. J Biol Chem. 2007;282(5):3182\u20137.","journal-title":"J Biol Chem"},{"issue":"14","key":"440_CR24","doi-asserted-by":"publisher","first-page":"1159307","DOI":"10.3389\/fphar.2023.1159307","volume":"9","author":"AM Ali","year":"2023","unstructured":"Ali AM, Adam H, Hailu D, Engidawork E, Howe R, Abula T, et\u00a0al. Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. Front Pharmacol. 2023;9(14):1159307.","journal-title":"Front Pharmacol"},{"issue":"1","key":"440_CR25","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.3324\/haematol.2015.134775","volume":"101","author":"K Chiengthong","year":"2016","unstructured":"Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, Seksan P, et\u00a0al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica. 2016;101(1):e24\u20136.","journal-title":"Haematologica"},{"issue":"4","key":"440_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/ph15040416","volume":"15","author":"Y Lee","year":"2022","unstructured":"Lee Y, Jang EJ, Yoon HY, Yee J, Gwak HS. Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pharmaceuticals. 2022;15(4):416.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"440_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3389\/fphar.2019.00916","volume":"27","author":"B Moradveisi","year":"2019","unstructured":"Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in Middle Eastern children with acute lymphoblastic leukemia. Front Pharmacol. 2019;27(10):916.","journal-title":"Front Pharmacol"},{"issue":"13","key":"440_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.941182","volume":"27","author":"HL Guo","year":"2022","unstructured":"Guo HL, Zhao YT, Wang WJ, Dong N, Hu YH, Zhang YY, et\u00a0al. Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: a promising \u201cMINT\u201d sequencing strategy and therapeutic \u201cDNA-TG\u201d monitoring. Front Pharmacol. 2022;27(13):941182.","journal-title":"Front Pharmacol"},{"key":"440_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.719803","volume":"9","author":"X Mao","year":"2021","unstructured":"Mao X, Yin R, Sun G, Zhou Y, Yang C, Fang C, et\u00a0al. Effects of TPMT, NUDT15, and ITPA genetic variants on 6-mercaptopurine toxicity for pediatric patients with acute lymphoblastic leukemia in Yunnan of China. Front Pediatr. 2021;9:719803.","journal-title":"Front Pediatr"},{"issue":"1","key":"440_CR30","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-021-87095-0","volume":"11","author":"Q Miao","year":"2021","unstructured":"Miao Q, Yan L, Zhou Y, Li Y, Zou Y, Wang L, et\u00a0al. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci Rep. 2021;11(1):7984.","journal-title":"Sci Rep"},{"issue":"2","key":"440_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00535-017-1416-0","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53(2):172\u201380.","journal-title":"J Gastroenterol"},{"issue":"2","key":"440_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12185-021-03237-0","volume":"115","author":"X Wei","year":"2022","unstructured":"Wei X, Zhuang J, Li N, Zheng B, Sun H, Cai J, et\u00a0al. NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China. Int J Hematol. 2022;115(2):278\u201386.","journal-title":"Int J Hematol"},{"issue":"12\u201313","key":"440_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14622416.2024.2409060","volume":"25","author":"A \u0160mid","year":"2024","unstructured":"\u0160mid A, Urban\u010di\u010d D, \u017dlajpah JV, Stollarova N, Prelog T, Kav\u010di\u010d M, et\u00a0al. Genetic profiling of NUDT15 in the Slovenian population. Pharmacogenomics. 2024;25(12\u201313):515\u201325.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"440_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/clinpract15060114","volume":"15","author":"K Wro\u0144ski","year":"2025","unstructured":"Wro\u0144ski K, Holecki MT, Boguszewska N, Skrzypczak-Zieli\u0144ska M, Chudek JT. Bone marrow aplasia and neutropenic fever following azathioprine dose escalation in a TPMT-deficient patient with Crohn\u2019s disease and psoriatic arthritis\u2014A CARE\u2013compliant case. Clinics and Practice. 2025;15(6):114.","journal-title":"Clinics and Practice"},{"issue":"11","key":"440_CR35","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1111\/imj.15746","volume":"52","author":"S Afrin","year":"2022","unstructured":"Afrin S, Simms LA, Lord A, Radford\u2010Smith GL. Nudix hydrolase 15 ( NUDT15 ) loss\u2010of\u2010function variants in an Australian inflammatory bowel disease population. Intern Med J. 2022;52(11):1971\u20137.","journal-title":"Intern Med J"},{"issue":"9","key":"440_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"SK Yang","year":"2014","unstructured":"Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et\u00a0al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017\u201320.","journal-title":"Nat Genet"},{"issue":"6","key":"440_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0000000000000282","volume":"27","author":"T Moriyama","year":"2017","unstructured":"Moriyama T, Nishii R, Lin TN, Kihira K, Toyoda H, Jacob N, et\u00a0al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2017;27(6):236\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"440_CR38","doi-asserted-by":"publisher","first-page":"784712","DOI":"10.3389\/fphar.2021.784712","volume":"12","author":"K Khaeso","year":"2021","unstructured":"Khaeso K, Udayachalerm S, Komvilaisak P, Chainansamit S-O, Suwannaying K, Laoaroon N, et\u00a0al. Meta-analysis of NUDT15 genetic polymorphism on thiopurine-induced myelosuppression in Asian populations. Front Pharmacol. 2021;12:784712.","journal-title":"Front Pharmacol"},{"key":"440_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2018.07.021","volume":"135","author":"S Cargnin","year":"2018","unstructured":"Cargnin S, Genazzani AA, Canonico PL, Terrazzino S. Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacol Res. 2018;135:102\u201311.","journal-title":"Pharmacol Res"},{"issue":"21","key":"440_CR40","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1093\/hmg\/dds302","volume":"21","author":"G Stocco","year":"2012","unstructured":"Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, et\u00a0al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012;21(21):4793\u2013804.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"440_CR41","doi-asserted-by":"publisher","first-page":"30244","DOI":"10.1038\/srep30244","volume":"6","author":"A Smid","year":"2016","unstructured":"Smid A, Karas-Kuzelicki N, Jazbec J, Mlinaric-Rascan I. PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep. 2016;6(1):30244.","journal-title":"Sci Rep"},{"issue":"3","key":"440_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41397-019-0130-0","volume":"20","author":"R Franca","year":"2020","unstructured":"Franca R, Stocco G, Favretto D, Giurici N, Del Rizzo I, Locatelli F, et\u00a0al. PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenom J. 2020;20(3):415\u201325.","journal-title":"Pharmacogenom J"},{"issue":"38","key":"440_CR43","doi-asserted-by":"publisher","first-page":"35669","DOI":"10.1074\/jbc.M103792200","volume":"276","author":"RG Tirona","year":"2001","unstructured":"Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C. J Biol Chem. 2001;276(38):35669\u201375.","journal-title":"J Biol Chem"},{"issue":"35","key":"440_CR44","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","volume":"27","author":"LR Trevi\u00f1o","year":"2009","unstructured":"Trevi\u00f1o LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et\u00a0al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. JCO. 2009;27(35):5972\u20138.","journal-title":"JCO"},{"issue":"6","key":"440_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"LB Ramsey","year":"2013","unstructured":"Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, et\u00a0al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898\u2013904.","journal-title":"Blood"},{"issue":"26","key":"440_CR46","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, M\u00f6ricke A, et\u00a0al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121(26):5145\u201353.","journal-title":"Blood"},{"issue":"12","key":"440_CR47","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/pbc.25191","volume":"61","author":"H Zhang","year":"2014","unstructured":"Zhang H, He X, Wang C, Wang Y, Chen Y, Li J, et\u00a0al. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high\u2010dose methotrexate. Pediatr Blood Cancer. 2014;61(12):2203\u20137.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00440-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:03:08Z","timestamp":1782385388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00440-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00440-z","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Isidora Curic, Nikola Kotur, Bojan Ristivojevic, Djordje Pavlovic, Marina Jelovac, Katarina Krstajic, Mia Radosevic, Ana Djordjevic, Sonja Pavlovic, Jelena Roganovic and Branka Zukic have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration. The study was approved by the Ethics Committee of the Clinical Hospital Center Rijeka (No. 2170-29-02\/1-23-4 from July 28, 2023.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}